胆道恶性梗阻性疾病的非手术治疗

尹靖阳; 杨慷

doi:10.3969/j.issn.1001-5256.2019.03.052

胆道恶性梗阻性疾病的非手术治疗

DOI: 10.3969/j.issn.1001-5256.2019.03.052

尹靖阳,
杨慷

重庆医科大学附属第二医院肝胆外科

详细信息

中图分类号: R730.5
计量
- 文章访问数: 1342
- HTML全文浏览量: 23
- PDF下载量: 287
- 被引次数: 0
出版历程
- 出版日期: 2019-03-20

Nonsurgical treatment of malignant biliary obstructive diseases

Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University

摘要

摘要: 胆道恶性梗阻是由各种肝脏、胆道、胰腺原发或转移性恶性肿瘤引起,以梗阻性黄疸、肝功能损伤、胆管炎为主要临床表现的一类疾病。此类患者早期诊断较为困难,临床确诊时已进展到中晚期,大部分进展期患者已无手术切除机会。胆道引流和胆道支架置入等非手术治疗技术在此类不可切除胆道恶性梗阻性疾病患者的姑息治疗中发挥着重要作用。胆道腔内射频消融术、胆管腔内近距离放射、光动力疗法等新技术的应用进一步推动了胆道引流等非手术治疗方法的改进与疗效提高。随着研究的不断完善,这些技术有望更加规范地应用于临床实践。
- 胆道疾病 /
- 引流术 /
- 支架 /
- 综述
Abstract: Malignant biliary obstructive diseases are caused by various primary or metastatic malignancies of the liver, the biliary tract, andthe pancreas, with major clinical manifestations of obstructive jaundice, liver impairment, and cholangitis. Early diagnosis of such patients isdifficult, and most patients are in an advanced stage at the time of diagnosis and lose the opportunity for surgical resection. Nonsurgical treat-ment techniques including biliary drainage and biliary stent implantation play an important role in palliative treatment of patients with unre-sectable malignant biliary obstructive diseases. The application of new techniques, such as biliary radiofrequency ablation, intraductalbrachytherapy, and photodynamic therapy, further promotes the improvement in the effect of nonsurgical treatment methods including biliarydrainage. With the help of related research advances, these techniques can be applied in clinical practice in a standardized way.
- biliary tract diseases /
- drainage /
- stents /
- review

HTML全文

参考文献(32)

[1] XU XD, DAI JJ, QIAN JQ, et al. Prevention of pancreatitis afterpapillary balloon dilatation by nasobiliary drainage:A randomizedcontrolled trial[J]. Dig Dis Sci, 2015, 60 (4) :1087-1091.

[2] XU G. Clinical effect of biliary metal stent implantation via en-doscopic retrograde cholangiopancreatography in treatment ofunresectable malignant extrahepatic biliary obstruction[J]. JClin Hepatol, 2018, 34 (2) :337-340. (in Chinese) 徐刚.经内镜逆行胰胆管造影胆道金属支架置入治疗不可切除肝外胆道恶性梗阻的效果观察[J].临床肝胆病杂志, 2018, 34 (2) :337-340.

[3] MUKAI T, YASUDA I, NAKASHIMA M, et al. Metallic stentsare more efficacious than plastic stents in unresectable malig-nant hilar biliary strictures:A randomized controlled trial[J]. JHepatobiliary Pancreat Sci, 2013, 20 (2) :214-222.

[4] DOWSETT JF, VAIRA D, HATFIELD AR, et al. Endoscopic biliarytherapy using the combined percutaneous and endoscopic tech-nique[J]. Gastroenterology, 1989, 96 (4) :1180-1186.

[5] VIENNE A, HOBEIKA E, GOUYA H, et al. Prediction of drain-age effectiveness during endoscopic stenting of malignant hilarstrictures:The role of liver volume assessment[J]. Gastroint-est Endosc, 2010, 72 (4) :728-735.

[6] UPPAL DS, WANG AY. Advances in endoscopic retrogradecholangiopancreatography for the treatment of cholangiocarcino-ma[J]. World J Gastrointest Endosc, 2015, 7 (7) :675-687.

[7] KERDSIRICHAIRAT T, ARAIN MA, ATTAM R, et al. Endo-scopic drainage of> 50%of liver in malignant hilar biliary ob-struction using metallic or fenestrated plastic stents[J]. ClinTransl Gastroenterol, 2017, 8 (8) :e115.

[8] SAWAS T, AL HALABI S, PARSI MA, et al. Self-expandablemetal stents versus plastic stents for malignant biliary obstruc-tion:A meta-analysis[J]. Gastrointest Endosc, 2015, 82 (2) :256-267. e7.

[9] ALMADI MA, BARKUN A, MARTEL M. Plastic vs. self-ex-pandable metal stents for palliation in malignant biliary obstruc-tion:A series of meta-analyses[J]. Am J Gastroenterol, 2017, 112 (2) :260-273.

[10] MARTINEZ JM, ANENE A, BENTLEY TG, et al. Cost effec-tiveness of metal stents in relieving obstructive jaundice in pa-tients with pancreatic cancer[J]. J Gastrointest Cancer, 2017, 48 (1) :58-65.

[11] RERKNIMITR R, ANGSUWATCHARAKON P, RATANACHU-EKT, et al. Asia-Pacific consensus recommendations for endo-scopic and interventional management of hilar cholangiocarcino-ma[J]. J Gastroenterol Hepatol, 2013, 28 (4) :593-607.

[12] TANGUTURI SK, WO JY, ZHU AX, et al. Radiation therapy forliver tumors:Ready for inclusion in guidelines?[J]. Oncolo-gist, 2014, 19 (8) :868-879.

[13] HAN K, KO HK, KIM KW, et al. Radiofrequency ablation inthe treatment of unresectable intrahepatic cholangiocarcino-ma:Systematic review and meta-analysis[J]. J Vasc IntervRadiol, 2015, 26 (7) :943-948.

[14] STEEL AW, POSTGATE AJ, KHORSANDI S, et al. Endoscop-ically applied radiofrequency ablation appears to be safe in thetreatment of malignant biliary obstruction[J]. Gastrointest En-dosc, 2011, 73 (1) :149-153.

[15] SOFI AA, KHAN MA, DAS A, et al. Radiofrequency ablationcombined with biliary stent placement versus stent placement a-lone for malignant biliary strictures:A systematic review and meta-analysis[J]. Gastrointest Endosc, 2018, 87 (4) :944-951.

[16] YANG J, WANG J, ZHOU H, et al. Efficacy and safety of en-doscopic radiofrequency ablation for unresectable extrahepaticcholangiocarcinoma:A randomized trial[J]. Endoscopy, 2018, 50 (8) :751-760.

[17] HAN SY, SONG GA, KIM DU, et al. Bile duct patency main-tained after intraductal radiofrequency ablation in a case ofhepatocellular cholangiocarcinoma with bile duct invasion[J].Clin Endosc, 2018, 51 (2) :201-205.

[18] CAMUS M, NAPOLEON B, VIENNE A, et al. Efficacy and safetyof endobiliary radiofrequency ablation for the eradication of resid-ual neoplasia after endoscopic papillectomy:A multicenter pro-spective study[J]. Gastrointest Endosc, 2018, 88 (3) :511-518.

[19] ZHOU C, WEI B, GAO K, et al. Biliary tract perforation follow-ing percutaneous endobiliary radiofrequency ablation:A reportof two cases[J]. Oncol Lett, 2016, 11 (6) :3813-3816.

[20] CHEN Y, WANG XL, YAN ZP, et al. HDR-192Ir intraluminalbrachytherapy in treatment of malignant obstructive jaundice[J]. World J Gastroenterol, 2004, 10 (23) :3506-3510.

[21] VALEK V, KYSELA P, KALA Z, et al. Brachytherapy and per-cutaneous stenting in the treatment of cholangiocarcinoma:Aprospective randomised study[J]. Eur J Radiol, 2007, 62 (2) :175-179.

[22] YOSHIOKA Y, OGAWA K, OIKAWA H, et al. Impact of in-traluminal brachytherapy on survival outcome for radiation ther-apy for unresectable biliary tract cancer:A propensity-scorematched-pair analysis[J]. Int J Radiat Oncol Biol Phys, 2014, 89 (4) :822-829.

[23] XU X, LI J, WU J, et al. A systematic review and meta-anal-ysis of intraluminal brachytherapy versus stent alone in thetreatment of malignant obstructive jaundice[J]. CardiovascIntervent Radiol, 2018, 41 (2) :206-217.

[24] LI S, HE X, DANG L, et al. Efficacy of (125) I versus non- (125) I combined with transcatheter arterial chemoembolization for thetreatment of unresectable hepatocellular carcinoma with obstruc-tive jaundice[J]. Dig Dis Sci, 2018, 63 (2) :321-328.

[25] ZHU HD, GUO JH, HUANG M, et al. Irradiation stents vs. con-ventional metal stents for unresectable malignant biliary obstruc-tion:A multicenter trial[J]. J Hepatol, 2018, 68 (5) :970-977.

[26] YANG J, SHEN H, JIN H, et al. Treatment of unresectable ex-trahepatic cholangiocarcinoma using hematoporphyrin photo-dynamic therapy:A prospective study[J]. PhotodiagnosisPhotodyn Ther, 2016, 16:110-118.

[27] DOLAK W, SCHWAIGHOFER H, HELLMICH B, et al. Photo-dynamic therapy with polyhematoporphyrin for malignant biliaryobstruction:A nationwide retrospective study of 150 consecu-tive applications[J]. United European Gastroenterol J, 2017, 5 (1) :104-110.

[28] MOOLE H, TATHIREDDY H, DHARMAPURI S, et al. Success ofphotodynamic therapy in palliating patients with nonresectablecholangiocarcinoma:A systematic review and meta-analysis[J]. World J Gastroenterol, 2017, 23 (7) :1278-1288.

[29] SHIM CS, CHEON YK, CHA SW, et al. Prospective study ofthe effectiveness of percutaneous transhepatic photodynamictherapy for advanced bile duct cancer and the role of intraduc-tal ultrasonography in response assessment[J]. Endoscopy, 2005, 37 (5) :425-433.

[30] WAGNER A, WIEDMANN M, TANNAPFEL A, et al. Neoadju-vant down-sizing of hilar cholangiocarcinoma with photody-namic therapy-long-term outcome of a phase II pilot study[J]. Int J Mol Sci, 2015, 16 (11) :26619-26628.

[31] STRAND DS, COSGROVE ND, PATRIE JT, et al. ERCP-di-rected radiofrequency ablation and photodynamic therapy areassociated with comparable survival in the treatment of unre-sectable cholangiocarcinoma[J]. Gastrointest Endosc, 2014, 80 (5) :794-804.

[32] WENTRUP R, WINKELMANN N, MITROSHKIN A, et al. Pho-todynamic therapy plus chemotherapy compared with photo-dynamic therapy alone in hilar nonresectable cholangiocarcino-ma[J]. Gut Liver, 2016, 10 (3) :470-475.

施引文献

资源附件(0)

访问统计